NCT03128034View on ClinicalTrials.gov

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

June 30, 2027

Study Completion Date

March 31, 2029

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid LeukemiaRefractory Mixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia
Interventions
DRUG

Cyclosporine

Given PO or IV

DRUG

Fludarabine Phosphate

Given IV

DRUG

Mycophenolate Mofetil

Given PO or IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC transplant

RADIATION

Pretargeted Radioimmunotherapy

Given 211\^At-BC8-B10 IV

RADIATION

Total-Body Irradiation

Undergo TBI

RADIATION

Pretargeted Radioimmunotherapy

Given 131\^I-BC8-B10 IV

PROCEDURE

Biospecimen Collection

Undergo blood and bone marrow aspirate sample collection

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER